PFE’s Oncology & Obesity Pipeline Position It for Post-LOE Growth

Pfizer expects a significant revenue hit from the loss of exclusivity for several key products between 2026 and 2030, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, all facing patent expirations. The company says strengthened R&D through mergers and acquisitions, successful data readouts and pivotal program starts in 2025 will position it for sustainable growth after those losses.

The company has advanced its oncology pipeline, with several candidates entering late-stage development. Late-stage oncology assets include vepdegestrant, a small-molecule PROTAC for ER+/HER2- metastatic breast cancer; atirmociclib, a CDK4 inhibitor for first-line HR+/HER2- metastatic breast cancer; and sigvotatug vedotin, an antibody-drug conjugate for metastatic non-small cell lung cancer.

Sasanlimab is under regulatory review in the United States and European Union for BCG-naive high-risk non-muscle invasive bladder cancer. Pfizer in-licensed exclusive global ex-China rights to PF-08634404, a dual PD-1/VEGF inhibitor, from China’s 3SBio earlier this year. The company says dual PD-1/VEGF inhibitors are intended to address limitations of single-target cancer therapies such as Merck & Co.’s Keytruda and could reshape standard-of-care options. Pfizer expects to have eight or more blockbuster oncology medicines by 2030.

Outside oncology, late-stage programs include an mRNA combined flu/COVID vaccine and osivelotor for sickle cell disease. Pfizer is also pursuing label expansions for approved products including Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio. Last month, the FDA approved Padcev in combination with Merck & Co.’s Keytruda for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.

Pfizer is also bolstering its obesity pipeline to challenge market leaders Eli Lilly and Novo Nordisk. The $10 billion acquisition of Metsera in November added four clinical-stage incretin and amylin programs expected to generate multibillion-dollar peak sales. This month the company in-licensed exclusive global rights to YP05002, an oral small-molecule GLP-1 receptor agonist, from China’s YaoPharma. Combined with in-house programs, including a GIPR antagonist candidate, Pfizer says it now has a diverse obesity portfolio.